RE: Bargain10 Sep 2018 11:26
The point of P3 is to prove that the treatment satisfies a statistical measurement of efficacy versus a control.
The statistical significance was not achieved over the whole trial, therefore the trial failed.
Lupuzor achieved the statistically significance for a considerable subset of trial patients, providing COMPLETE REMISSION for five patients. Since FIVE MILLION PEOPLE suffer from Lupus, MILLIONS of patients can benefit from Lupus, which is why the MAP is continuing, with patients being given a NON-FDA APPROVED drug.
it is not THAT difficult to see Lupuzor as a POTENTIAL BLOCKBUSTER, as it was described in the latest RNS.